In particular, we find that PD-L1-positive pancreatic cancer cells can be effectively treated with a combinatorial treatment involving the inhibition of PD-L1/PD-1 interaction and PMN-MDSC depletion. This evidence concerns the gene PDCD1 and pancreatic neoplasm.